PPP induced IGF1R degradation appears dependent on the MDM2 E3 ligase, as altered expression was abrogated in cells expressing truncated MDM2 lacking the ligase domain.95 AXL1717, a bio-orally available analogue of PPP has since entered phase 2 clinical trials for treatment of non-small cell lung cancer, although it was found to provide no benefit for progression or overall survival.96 Here, MDM2 is linked to non-small cell lung carcinoma.